Juvenile systemic lupus erythematosus in Turkey: demographic,clinical and laboratory features with disease activity and outcome

Abstract

Objectives

This paper aims to assess in a retrospective fashion the clinical and laboratory features, severity and outcome of juvenile systemic lupus erythematosus (jSLE) from a referral center in Turkey.

Methods

We have included all jSLE patients (n = 92) diagnosed according to the revised American College of Rheumatology 1997 criteria between January 2004 and January 2017.

Results

The most prevalent clinical feature in our cohort was mucocutaneous manifestations (97.8%), followed by constitutional (81.5%), hematological (59.8%) and musculoskeletal manifestations (56.5%). Renal involvement was observed in 38% (n = 35) of the patients, whereas biopsy-proven lupus nephritis was detected in 29.3% (n = 27) of the cohort. Neurologic involvement was seen in 15 (16.3%) individuals. Among the patients positive for anticardiolipin IgM and/or IgG (n = 11, 12%), only three developed antiphospholipid antibody syndrome. The mean SLEDAI-2K scores at disease onset (10.5 ± 4.8) showed a substantial decrease at last visit (4.3 ± 4.6). One-quarter of the patients (26.1%, n = 24) had damage according to the PedSDI criteria with a mean score of 0.45 ± 1.0 (range 0–7). When the PedSDI damage items were evaluated individually, growth failure was the most frequent damage criterion (n = 6), followed by seizure (n = 5). Two patients died during the designated study period of end-stage renal disease. The five-year and 10-year survival rate of our cohort was 100% and 94.4%, respectively.

Conclusions

Given the lower frequency of nephritis and central nervous system disease and lower basal disease activity and damage scores, we could conclude that children with jSLE in Turkey have a more favorable course compared to Asian and African American children, as expected from Caucasian ethnicity.

Keywords

Juvenile systemic lupus erythematosus SLEDAI PedSDI nephritis neurologic involvement mortality

Get full access to this article

View all access options for this article.

References

Couture

Silverman

. Update on the pathogenesis and treatment of childhood-onset systemic lupus erythematosus. Curr Opin Rheumatol 2016; 28: 488–496.

Thorbinson

Oni

Smith

Midgley

Beresford

. Pharmacological management of childhood-onset systemic lupus erythematosus. Paediatr Drugs 2016; 18: 181–195.

Pineles

Valente

Warren

Peterson

Lehman

Moorthy

. Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus 2011; 20: 1187–1192.

Hiraki

Benseler

Tyrrell

Harvey

Hebert

Silverman

. Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol 2009; 36: 2539–2546.

Artim-Esen

Şahin

Çene

et al.

Comparison of disease characteristics, organ damage, and survival in patients with juvenile-onset and adult-onset systemic lupus erythematosus in a combined cohort from 2 tertiary centers in Turkey. J Rheumatol 2017; 44: 619–625.

Ambrose

Morgan

Galloway

et al.

Differences in disease phenotype and severity in SLE across age groups. Lupus 2016; 25: 1542–1550.

Hoffman

Lauwerys

De Keyser

et al.

Juvenile-onset systemic lupus erythematosus: Different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis 2009; 68: 412–415.

Abulaban

Brunner

. Biomarkers for childhood-onset systemic lupus erythematosus. Curr Rheumatol Rep 2015; 17: 471–471.

Binder

Edelbauer

. Use of biomarkers in the management of children with lupus. Curr Rheumatol Rep 2013; 15: 312–312.

10.

Sahin

Adrovic

Barut

et al.

Pentraxin-3 levels are associated with vasculitis and disease activity in childhood-onset systemic lupus erythematosus. Lupus 2017; 26: 1089–1094.

11.

Hiraki

Feldman

Liu

et al.

Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum 2012; 64: 2669–2676.

12.

Kamphuis

Silverman

. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010; 6: 538–546.

13.

Groot

de Graeff

Avcin

et al.

European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: The SHARE initiative. Ann Rheum Dis 2017; 76: 1788–1796.

14.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

15.

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608.

16.

Weening

D’Agati

Schwartz

et al.

The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241–250.

17.

Gladman

Ibañez

Urowitz

. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 288–291.

18.

Gutiérrez-Suárez

Ruperto

Gastaldi

et al.

A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2989–2996.

19.

Bader-Meunier

Armengaud

Haddad

et al.

Initial presentation of childhood-onset systemic lupus erythematosus: A French multicenter study. J Pediatr 2005; 146: 648–653.

20.

Hiraki

Benseler

Tyrrell

Hebert

Harvey

Silverman

. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: A longitudinal study. J Pediatr 2008; 152: 550–556.

21.

Lukic

Malcic

et al.

Childhood-onset systemic lupus erythematosus in Croatia: Demographic, clinical and laboratory features, and factors influencing time to diagnosis. Clin Exp Rheumatol 2013; 31: 803–812.

22.

Abdel-Hafez

Abdel-Nabi

. Juvenile systemic lupus erythematosus: Onset patterns and short-term outcome in Egyptian children, a single-center experience. Lupus 2015; 24: 1455–1461.

23.

Tan

Hoh

Win

Chan

Das

Arkachaisri

. Childhood-onset systemic lupus erythematosus in Singapore: Clinical phenotypes, disease activity, damage, and autoantibody profiles. Lupus 2015; 24: 998–1005.

24.

Ramírez Gómez

Uribe Uribe

Osio Uribe

et al.

Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus 2008; 17: 596–604.

25.

Borba

Araujo

Bonfá

Shinjo

. Clinical and immunological features of 888 Brazilian systemic lupus patients from a monocentric cohort: Comparison with other populations. Lupus 2013; 22: 744–749.

26.

Gulay

Dans

. Clinical presentations and outcomes of Filipino juvenile systemic lupus erythematosus. Pediatr Rheumatol Online J 2011; 9: 7–7.

27.

Supavekin

Chatchomchuan

Pattaragarn

Suntornpoch

Sumboonnanonda

. Pediatric systemic lupus erythematosus in Siriraj Hospital. J Med Assoc Thai 2005; 88(Suppl 8): S115–S123.

28.

Lewandowski

Schanberg

Thielman

et al.

Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa. Lupus 2017; 26: 186–194.

29.

Dung

Loan

Nielsen

Zak

Petersen

. Juvenile systemic lupus erythematosus onset patterns in Vietnamese children: A descriptive study of 45 children. Pediatr Rheumatol Online J 2012; 10: 38–38.

30.

Rubtsov

Rubtsova

Kappler

Marrack

. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev 2010; 9: 494–498.

31.

Adelowo

Olaosebikan

Animashaun

Akintayo

. Juvenile systemic lupus erythematosus in Nigeria. Lupus 2017; 26: 329–333.

32.

Concannon

Rudge

Yan

Reed

. The incidence, diagnostic clinical manifestations and severity of juvenile systemic lupus erythematosus in New Zealand Maori and Pacific Island children: The Starship experience (2000–2010). Lupus 2013; 22: 1156–1161.

33.

Huggins

Holland

Brunner

. Organ involvement other than lupus nephritis in childhood-onset systemic lupus erythematosus. Lupus 2016; 25: 857–863.

34.

Brunner

Silverman

Bombardier

Feldman

. Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002; 46: 436–444.